GlaxoSmithKline Pharmaceuticals, the leading MNC in India, recorded smart growth in bottomline during the first quarter ended March 2006. Its net profit went up sharply by 116 per cent to Rs 101.23 core from Rs 46.91 crore in the similar period of last year. Its net sales touched to Rs 426.16 crore from Rs 276.24 crore, a rise of 54.3 per cent. The earning per share worked out to Rs 12.2 as compared to Rs 6.3 in the last period.

The operating profit before interest, depreciation and taxation moved up by 92.9 per cent to Rs 163.34 crore from Rs 84.68 crore. Its taxation provision increased to Rs 56.14 crore from Rs 26.20 crore in the previous period. However, exceptional items in respect of provision for pricing of a formulation amounted to Rs 2.20 crore as against Rs 7.84 crore. The company is selling its Animal health business for a consideration of Rs 20.71 crore.